Neumentum to Participate in the Jefferies Virtual London Healthcare Conference
MORRISTOWN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during the Jefferies Virtual London Healthcare Conference being held November 17 – November 19, 2020.
About Neumentum: Addressing a National Health Emergency
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the risks of abuse, misuse and diversion seen with opioids, or opioid-induced side effects including potentially life-threatening respiratory depression.
Opioid use is considered a critical public health concern in the US. In 2018, 9.9 million people over age of 12 reported misusing prescription opioid pain relievers1, and opioids were involved in 46,802 overdose deaths.2 Opioids also account for over 305,000 emergency department visits annually for non-fatal overdoses.3 Despite these staggering statistics, and the frequently reported opioid-induced side effects such as nausea, vomiting, constipation and somnolence, 168 million prescriptions – over 51 prescriptions per 100 Americans – were written for opioids in 2018.4
Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to moderately severe chronic pain, was licensed in late 2019 from Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion.
Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit www.Neumentum.com.
CEO & Co-founder
Westwicke, an ICR company
 SAMSHA, Key Substance Use and Mental Health Indicators in the US: Results from the 2018 National Survey on Drug Use and Health. P13, Fig 10.
 Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL. MMWR Morb Mortal Wkly Rep 2020; 69:290–297
 Vivolo-Kantor AM, Hoots BE, Scholl L, et al. MMWR Morb Mortal Wkly Rep 2020;69:371–376
 www.cdc.gov/drugoverdose/maps/rxrate-maps.html, accessed 16 Jul 2020